サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1417393

内視鏡的逆行性胆管膵管造影（ERCP）の世界市場：動向、予測、競合分析（～2030年）

Endoscopic Retrograde Cholangiopancreatography Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 - page report
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

内視鏡的逆行性胆管膵管造影（ERCP）の世界市場：動向、予測、競合分析（～2030年）
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

内視鏡的逆行性胆管膵管造影の動向と予測

世界の内視鏡的逆行性胆管膵管造影の市場規模は、2024～2030年にかけてCAGR 5.5％で成長し、2030年までに推定19億米ドルに達すると予測されています。この市場の主な促進要因は、がん罹患率の上昇、低侵襲手技・手術への志向の高まり、政府やヘルスケア機関からの財政的コミットメントの高まりです。世界の内視鏡的逆行性胆管膵管造影市場の将来は、病院や外来手術センター・クリニック市場での機会で有望視されています。

内視鏡的逆行性胆管膵管造影市場の洞察

Lucintelは、消化器疾患の罹患率の増加により、予測期間中、内視鏡治療装置が最大セグメントであり続けると予測しています。

この市場の中で、病院はこれらの施設で幅広いERCPデバイスを利用できるため、最大のセグメントであり続けると思われます。

北米は、がん患者の増加や先進的なERCPツールのイントロダクションより、予測期間中最大の地域であり続けると思われます。

よくある質問

Q1.市場規模は？

A1.世界の内視鏡的逆行性胆管膵管造影市場は、2030年までに推定19億米ドルに達すると予想されています。

Q2.市場の成長予測は？

A2.世界の内視鏡的逆行性胆管膵管造影市場は、2024～2030年にかけてCAGR 5.5%で成長する見込みです。

Q3.市場の成長に影響を与える主な促進要因は？

A3.この市場の主な促進要因は、がん罹患率の上昇、低侵襲手技・手術への志向の高まり、政府やヘルスケア機関からの財政的コミットメントの増大です。

Q4.市場の主要セグメントは？

A4.内視鏡的逆行性胆管膵管造影市場の将来は、病院および外来手術センター・クリニック市場での機会により有望視されます。

Q5.市場の主要企業は？

A5.内視鏡的逆行性胆管膵管造影の主要企業は以下の通りです。

  • Hobbs Medical
  • STERIS
  • Merit Medical Systems
  • TeleMed Systems
  • Changzhou Health Microport Medical Device

Q6.今後、最大となる市場セグメントは？

A6.Lucintelは、消化器疾患の罹患率の増加により、予測期間中、内視鏡治療装置が最大セグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は？

A7.北米は、がん患者の増加や先進的なERCPツールのイントロダクションより、予測期間中も最大地域であり続ける。

Q8.レポートのカスタマイズは可能？

A8.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の内視鏡的逆行性胆管膵管造影市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 産業の促進要因と課題

第3章 市場動向と予測分析（2018～2030年）

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の内視鏡的逆行性胆管膵管造影の市場動向（2018～2023年）と予測（2024～2030年）
  • 世界の内視鏡的逆行性胆管膵管造影市場：製品別
    • 内視鏡
    • 内視鏡治療装置
    • 可視化システム
    • エネルギーデバイス
    • その他
  • 世界の内視鏡的逆行性胆管膵管造影市場：手順別
    • 胆道括約筋切開術
    • 胆道ステント留置術
    • 胆道透析
    • 膵括約筋切開術
    • 膵管ステント留置術
    • 膵管拡張術
  • 世界の内視鏡的逆行性胆管膵管造影市場：最終用途別
    • 病院
    • 外来手術センター・クリニック
    • その他

第4章 市場動向と予測分析：地域別（2018～2030年）

  • 世界の内視鏡的逆行性胆管膵管造影市場：地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 製品別
    • 手順別
    • 最終用途別
    • 地域別
  • 世界の内視鏡的逆行性胆管膵管造影市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の内視鏡的逆行性胆管膵管造影市場の能力拡大
    • 世界の内視鏡的逆行性胆管膵管造影市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Hobbs Medical
  • STERIS
  • Merit Medical Systems
  • TeleMed Systems
  • Changzhou Health Microport Medical Device
目次

Endoscopic Retrograde Cholangiopancreatography Trends and Forecast

The future of the global endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets. The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030 with a CAGR of 5.5% from 2024 to 2030. The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.

A more than 150-page report is developed to help in your business decisions.

Endoscopic Retrograde Cholangiopancreatography by Segment

The study includes a forecast for the global endoscopic retrograde cholangiopancreatography by product, procedure, end use, and region.

Endoscopic Retrograde Cholangiopancreatography Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Endoscopes
  • Endotherapy Devices
  • Visualization Systems
  • Energy Devices
  • Others

Endoscopic Retrograde Cholangiopancreatography Market by Procedure [Shipment Analysis by Value from 2018 to 2030]:

  • Biliary Sphincterotomy
  • Biliary Stenting
  • Biliary Dialtation
  • Pancreatic Sphincterotomy
  • Pancreatic Duct Stenting
  • Pancreatic Duct Dilatation

Endoscopic Retrograde Cholangiopancreatography Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Ambulatory Surgery Centers & Clinics
  • Other

Endoscopic Retrograde Cholangiopancreatography Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Endoscopic Retrograde Cholangiopancreatography Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies endoscopic retrograde cholangiopancreatography companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the endoscopic retrograde cholangiopancreatography companies profiled in this report include-

  • Hobbs Medical
  • STERIS
  • Merit Medical Systems
  • TeleMed Systems
  • Changzhou Health Microport Medical Device

Endoscopic Retrograde Cholangiopancreatography Market Insights

Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.

Within this market, hospital will remain the largest segment due to availability of wide range of ERCP devices in these facilities.

North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.

Features of the Global Endoscopic Retrograde Cholangiopancreatography Market

Market Size Estimates: Endoscopic retrograde cholangiopancreatography market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Endoscopic retrograde cholangiopancreatography market size by product, procedure, end use, and region in terms of value ($B).

Regional Analysis: Endoscopic retrograde cholangiopancreatography market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, procedures, end uses, and regions for the endoscopic retrograde cholangiopancreatography market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the endoscopic retrograde cholangiopancreatography market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the endoscopic retrograde cholangiopancreatography market size?

Answer: The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030.

Q2. What is the growth forecast for endoscopic retrograde cholangiopancreatography market?

Answer: The global endoscopic retrograde cholangiopancreatography market is expected to grow with a CAGR of 5.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the endoscopic retrograde cholangiopancreatography market?

Answer: The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.

Q4. What are the major segments for endoscopic retrograde cholangiopancreatography market?

Answer: The future of the endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets.

Q5. Who are the key endoscopic retrograde cholangiopancreatography market companies?

Answer: Some of the key endoscopic retrograde cholangiopancreatography companies are as follows.

  • Hobbs Medical
  • STERIS
  • Merit Medical Systems
  • TeleMed Systems
  • Changzhou Health Microport Medical Device

Q6. Which endoscopic retrograde cholangiopancreatography market segment will be the largest in future?

Answer: Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.

Q7. In endoscopic retrograde cholangiopancreatography market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the endoscopic retrograde cholangiopancreatography market by product (endoscopes, endotherapy devices, visualization systems, energy devices, and others), procedure (biliary sphincterotomy, biliary stenting, biliary dialtation, pancreatic sphincterotomy, pancreatic duct stenting, and pancreatic duct dilatation), end use (hospitals, ambulatory surgery centers & clinics, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Endoscopic Retrograde Cholangiopancreatography Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Endoscopic Retrograde Cholangiopancreatography Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Endoscopic Retrograde Cholangiopancreatography Market by Product
    • 3.3.1: Endoscopes
    • 3.3.2: Endotherapy Devices
    • 3.3.3: Visualization Systems
    • 3.3.4: Energy Devices
    • 3.3.5: Others
  • 3.4: Global Endoscopic Retrograde Cholangiopancreatography Market by Procedure
    • 3.4.1: Biliary Sphincterotomy
    • 3.4.2: Biliary Stenting
    • 3.4.3: Biliary Dialtation
    • 3.4.4: Pancreatic Sphincterotomy
    • 3.4.5: Pancreatic Duct Stenting
    • 3.4.6: Pancreatic Duct Dilatation
  • 3.5: Global Endoscopic Retrograde Cholangiopancreatography Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Ambulatory Surgery Centers & Clinics
    • 3.5.3: Other

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Endoscopic Retrograde Cholangiopancreatography Market by Region
  • 4.2: North American Endoscopic Retrograde Cholangiopancreatography Market
    • 4.2.2: North American Endoscopic Retrograde Cholangiopancreatography Market by End Use: Hospitals, Ambulatory Surgery Centers & Clinics, and Other
  • 4.3: European Endoscopic Retrograde Cholangiopancreatography Market
    • 4.3.1: European Endoscopic Retrograde Cholangiopancreatography Market by Product: Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, and Others
    • 4.3.2: European Endoscopic Retrograde Cholangiopancreatography Market by End Use: Hospitals, Ambulatory Surgery Centers & Clinics, and Other
  • 4.4: APAC Endoscopic Retrograde Cholangiopancreatography Market
    • 4.4.1: APAC Endoscopic Retrograde Cholangiopancreatography Market by Product: Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, and Others
    • 4.4.2: APAC Endoscopic Retrograde Cholangiopancreatography Market by End Use: Hospitals, Ambulatory Surgery Centers & Clinics, and Other
  • 4.5: ROW Endoscopic Retrograde Cholangiopancreatography Market
    • 4.5.1: ROW Endoscopic Retrograde Cholangiopancreatography Market by Product: Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, and Others
    • 4.5.2: ROW Endoscopic Retrograde Cholangiopancreatography Market by End Use: Hospitals, Ambulatory Surgery Centers & Clinics, and Other

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Endoscopic Retrograde Cholangiopancreatography Market by Product
    • 6.1.2: Growth Opportunities for the Global Endoscopic Retrograde Cholangiopancreatography Market by Procedure
    • 6.1.3: Growth Opportunities for the Global Endoscopic Retrograde Cholangiopancreatography Market by End Use
    • 6.1.4: Growth Opportunities for the Global Endoscopic Retrograde Cholangiopancreatography Market by Region
  • 6.2: Emerging Trends in the Global Endoscopic Retrograde Cholangiopancreatography Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Endoscopic Retrograde Cholangiopancreatography Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Endoscopic Retrograde Cholangiopancreatography Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Hobbs Medical
  • 7.2: STERIS
  • 7.3: Merit Medical Systems
  • 7.4: TeleMed Systems
  • 7.5: Changzhou Health Microport Medical Device